Celltrion up on takeout rumors

Celltrion Inc. (KOSDAQ:068270) gained W4,100 to W47,400 on Wednesday on rumors in South Korean media outlets that multiple companies were engaged in talks to acquire the Korean biosimilar play. Roche (SIX:ROG; OTCQX:RHHBY), Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and AstraZeneca plc (LSE:AZN; NYSE:AZN) are all rumored to be in talks with Celltrion. Teva and Roche declined to comment, though Roche pointed out its "strategy is focused on R&D and developing new drugs." AstraZeneca and Celltrion could not be reached for comment. ...